Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening
- PMID: 10688498
- DOI: 10.1111/j.1471-0528.2000.tb11685.x
Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening
Abstract
Objective: To assess the performance of ultrasonography in a multimodal ovarian cancer screening strategy.
Design: Prospective ovarian cancer screening trial between December 1986 and June 1993.
Setting: General practice, occupational health departments and an ovarian cancer screening clinic at a London teaching hospital.
Population: Postmenopausal women, > or = 45 years with a raised CA125.
Methods: Volunteers with a CA125 > or = 30 U/mL underwent a pelvic ultrasound. Scans were classified as normal, abnormal (ovarian volume > or = 8.8 mL) or equivocal (normal volume with abnormal morphology). Abnormal ovarian morphology was subclassified as simple cyst (single, thin walled cyst with no septa or papillary projections) or complex (all other abnormalities). Volunteers with abnormal scans were referred for a gynaecological opinion. Follow up was via the cancer registry and postal questionnaires.
Main outcome measures: Sensitivity, specificity and positive predictive value of different ultrasound criteria for detection of index cancer (e.g. primary invasive epithelial carcinoma of the ovary and fallopian tube).
Results: Seven hundred and forty-one women underwent 1,219 scans and 20 index cancers occurred during a median follow up of 6 x 8 years. The sensitivity for detection of ovarian cancer of different ultrasound criteria was 100% for abnormal morphology, 89 x 5% for abnormal volume and 84% for complex morphology. The highest specificity (97%) and positive predictive value (37 x 2%) was achieved using complex morphology.
Conclusion: A variety of ultrasound criteria can achieve high sensitivity, specificity and positive predictive value for index cancers in postmenopausal women with an elevated CA125. Use of ovarian morphology to interpret ultrasound may increase sensitivity and use of complex ovarian morphology may increase the positive predictive value.
Similar articles
-
Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.BJOG. 2014 Dec;121 Suppl 7:35-9. doi: 10.1111/1471-0528.13211. BJOG. 2014. PMID: 25488086
-
Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation.Br J Cancer. 1999 Jul;80(10):1644-7. doi: 10.1038/sj.bjc.6690575. Br J Cancer. 1999. PMID: 10408412 Free PMC article.
-
Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses.Am J Obstet Gynecol. 2020 Jan;222(1):56.e1-56.e17. doi: 10.1016/j.ajog.2019.07.031. Epub 2019 Jul 24. Am J Obstet Gynecol. 2020. PMID: 31351062 Free PMC article.
-
The role of transvaginal ultrasound in screening for ovarian cancer.Climacteric. 2018 Jun;21(3):221-226. doi: 10.1080/13697137.2018.1433656. Epub 2018 Mar 1. Climacteric. 2018. PMID: 29490504 Review.
-
Benefits and limitations of ultrasonographic evaluation of uterine adnexal lesions in early detection of ovarian cancer.Clin Exp Obstet Gynecol. 2004;31(2):85-98. Clin Exp Obstet Gynecol. 2004. PMID: 15266758 Review.
Cited by
-
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.Lancet. 2016 Mar 5;387(10022):945-956. doi: 10.1016/S0140-6736(15)01224-6. Epub 2015 Dec 17. Lancet. 2016. PMID: 26707054 Free PMC article. Clinical Trial.
-
A new computer-aided diagnostic tool for non-invasive characterisation of malignant ovarian masses: results of a multicentre validation study.Eur Radiol. 2010 Aug;20(8):1822-30. doi: 10.1007/s00330-010-1750-6. Epub 2010 Mar 20. Eur Radiol. 2010. PMID: 20306081
-
C-Mannosyl tryptophan increases in the plasma of patients with ovarian cancer.Oncol Lett. 2020 Jan;19(1):908-916. doi: 10.3892/ol.2019.11161. Epub 2019 Nov 28. Oncol Lett. 2020. PMID: 31885719 Free PMC article.
-
A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.Gynecol Oncol. 2018 Jun;149(3):585-591. doi: 10.1016/j.ygyno.2018.03.050. Epub 2018 Mar 21. Gynecol Oncol. 2018. PMID: 29572027 Free PMC article.
-
GyneScan: an improved online paradigm for screening of ovarian cancer via tissue characterization.Technol Cancer Res Treat. 2014 Dec;13(6):529-39. doi: 10.7785/tcrtexpress.2013.600273. Epub 2013 Dec 6. Technol Cancer Res Treat. 2014. PMID: 24325128 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous